RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system

Neuropathology

Volumn 27, Issue 4, 2007, Pages 341-346

  Inda, María Del Mar ^a   Castresana, Javier S ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Medulloblastoma; Methylation; PNET; Promoter; RASSF1A

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANALYTIC METHOD; ARTICLE; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC DIFFERENCE; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; METHYLATION; NEUROECTODERM TUMOR; PRIORITY JOURNAL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; MIDDLE AGED; NEUROECTODERMAL TUMORS, PRIMITIVE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPRATENTORIAL NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 34447298660     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2007.00788.x     Document Type: Article

References (28)

1. Nicholson JC, Ross FM, Kohler JA, Ellison DW. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 1999 80 : 1322 1331.
2. Russo C, Pellarin M, Tingby O et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 1999 86 : 331 339.
3. Inda MM, Mercapide J, Munoz J et al. PTEN and DMBT1 homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. Oncol Rep 2004 12 : 1341 1347.
4. McComb RD, Burger PC. Pathologic analysis of primary brain tumors. Neurol Clin 1985 3 : 711 728.
5. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000 25 : 315 319.
6. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001 20 : 3563 3567.
7. Agathanggelou A, Honorio S, Macartney DP et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001 20 : 1509 1518.
8. Lo KW, Kwong J, Hui AB et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001 61 : 3877 3881.
9. Burbee DG, Forgacs E, Zochbauer-Muller S et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001 93 : 691 699.
10. Morrissey C, Martinez A, Zatyka M et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001 61 : 7277 7281.
11. Astuti D, Agathanggelou A, Honorio S et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001 20 : 7573 7577.
12. Yang Q, Zage P, Kagan D et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004 10 : 8493 8500.
13. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 2002 62 : 5906 5911.
14. Muhlisch J, Schwering A, Grotzer M et al. Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene 2006 25 : 1111 1117.
15. Chang Q, Pang JC, Li KK, Poon WS, Zhou L, Ng HK. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors. Hum Pathol 2005 36 : 1265 1272.
16. Fan X, Munoz J, Sanko SG, Castresana JS. PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas. Int J Oncol 2002 21 : 667 674.
17. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002 18 : 1427 1431.
18. Ehrlich M, Jiang G, Fiala E et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 2002 21 : 6694 6702.
19. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002 21 : 5400 5413.
20. Waha A, Koch A, Meyer-Puttlitz B et al. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003 62 : 1192 1201.
21. Ebinger M, Senf L, Wachowski O, Scheurlen W. Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathol Oncol Res 2004 10 : 17 21.
22. Fruhwald MC, O'Dorisio MS, Dai Z et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene 2001 20 : 5033 5042.
23. Fruhwald MC, O'Dorisio MS, Dai Z et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 2001 30 : 38 47.
24. Lee MG, Kim HY, Byun DS et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001 61 : 6688 6692.
25. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002 21 : 6835 6840.
26. Horiguchi K, Tomizawa Y, Tosaka M et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 2003 22 : 7862 7865.
27. Harada K, Toyooka S, Maitra A et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002 21 : 4345 4349.
28. Agathanggelou A, Cooper WN, Latif F. Role of the Ras association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005 65 : 3497 3508.